Concepedia

S. Holden

SH

Statistics

Publications

4

Citations

99

H-Index

4

Active since

2006

Affiliations

Sarah Cannon(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

S. Holden is an author at Sarah Cannon specializing in pharmacology, oncology, and immunotherapy.

Publications per year

2006–2009

4

Publications

4

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

M. Beeram, Ian E. Krop, Shanu Modi et al. · Journal of Clinical Oncology · 2007 · 40 citations

, , +17

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

S. Vukelja, Hope S. Rugo, C Vogel et al. · Cancer Research · 2009 · 27 citations

, , +17

A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors

Lia Gore, S. Holden, R.B. Cohen et al. · Annals of Oncology · 2006 · 18 citations · Full text

, , +11

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer.

IE Krop, M. Mita, HA Burris et al. · Cancer Research · 2009 · 14 citations

, , +16

1–4 of 4